The Short Version
The claim is largely supported. High-quality peer-reviewed studies project that GLP-1 drugs like Ozempic and Wegovy could avert tens of thousands of deaths annually and prevent over a million cardiovascular events within the 2036 timeframe. Clinical efficacy is well-established, and early population-level signals are emerging. However, these projections depend on expanded access, sustained adherence, and affordability improvements that are not yet guaranteed — and high costs and coverage gaps could limit who benefits and worsen health disparities.